January - March 2026

· Net sales amounted to kSEK 6,402 (4,776).

· Operating result, EBIT amounted to kSEK 1,077 (-3,152).

· Excl. Exchange rate differences kSEK 657 (-1,192).

· Result after tax amounted to kSEK 1,119 (-3,152).

· Earnings per share were SEK 0,07 (-0,19).

· Exchange rate differences kSEK 420 (-1,960).

(Other operating income/loss)

Significant Events during the period

· On February 26, Redsense announced first Clamp System sale to

UK clinic.

· On March 10, Redsense announces that the Company's

Nomination Committee proposes that Michael A Kraus be

elected as a new board member at the annual general meeting

on May 20, 2026.

Significant Events after the period

· No significant events after the period.

Message from the CEO

Early signs of increased usage and broader adoption

During the first quarter, we delivered year-on-year growth, with increased sales to new clinics and a broader customer mix beyond our two largest U.S. providers. Importantly, sales of disposables increased compared with the same period last year, indicating increased usage of previously installed systems and strengthening underlying demand.

At the beginning of the year, we implemented a revised pricing structure in the U.S., designed to address one of the key barriers to broader adoption - the per-treatment cost. The new structure redistributes pricing by increasing the capital device component while lowering the consumable cost per treatment.

This approach supports clinics in expanding usage across more patients, while also improving our ability to manage logistics and material cost variability. Early indications are that the change is contributing to increased usage, as reflected in higher disposable sales during the quarter. Part of the Q1 sales development also reflects a reconciliation of pricing on existing inventory in the U.S. ahead of the change, in addition to underlying growth.

During the quarter, we also increased our direct engagement with clinics, nurses, and provider leadership through several industry meetings and congresses in both Europe and the U.S. Feedback from these interactions has been encouraging, particularly around the revised pricing structure, usability improvements, and the potential to expand implementation into additional patient groups and care settings. Recent meetings in Germany and the U.S. further strengthened our dialogue with providers around broader adoption and rollout opportunities.

Operational stability and scalability

We have entered 2026 with a stronger operational base following the work carried out during 2025. Our cost structure is improved, and with the majority of our purchasing and sales conducted in U.S. dollars, our operational exposure to currency remains limited, although reported figures continue to be affected by translation into SEK.

Following increased customer payments and pricing adjustments at the start of the year, our cash position strengthened further after the end of the quarter, with cash on hand exceeding SEK 10 million at the end of April. In addition, we hold approximately SEK 9 million in inventory, largely consisting of consumables supporting the installed base and expected usage growth, while also securing delivery capacity and managing lead times. Together, this provides a solid base to support continued growth.

Operationally, we continue to improve efficiency and scalability, including onboarding an additional freight partner to improve delivery reliability and cost efficiency. The organisational and planning improvements implemented during 2025 are also contributing to more consistent execution across sales, supply chain, and production activities.

Progress in Clamp rollout and product development

We continue to strengthen our commercial footprint both within existing customer relationships and across new clinics. Outside the U.S., we completed the first commercial sales of the Redsense Clamp in the UK and are in ongoing discussions with several clinics as they work through budget allocation processes.

In Germany, we have been approved as a vendor with one of the largest non-profit dialysis providers, while in parallel completing a successful pilot with another large provider during the winter. Following positive clinical feedback, we are now in discussions regarding scope and timeline for broader implementation. This dual-track progress strengthens our position for larger volume opportunities in the market.

During the quarter, we also continued development work on updated fibre optic cables that further improve usability and reliability. Feedback from clinical pilots has been very positive, with significant improvements in ease of use and reduced handling complexity.

At the same time, we are progressing regulatory preparations for the Clamp, including additional testing as well as software and cybersecurity documentation. Once this work is finalised, we will conduct a readiness review and evaluate the most appropriate 510k submission pathway to introduce the Clamp in the US.

In parallel, we are preparing the launch of a digital training solution developed in close collaboration with our largest providers. The solution is designed to support consistent usage and address challenges related to staff turnover and has already received positive feedback from provider organisations.

Outlook

The first quarter shows early signs that the work carried out during 2025 is beginning to translate into increased usage and broader adoption. Our focus for 2026 remains disciplined execution - increasing end-customer usage in the U.S., progressing the rollout of the Clamp, and expanding into selected new markets.

By combining a stronger operational base with a more active commercial approach, we aim to increase adoption, support our customers more effectively, and reach more patients with improved safety in dialysis care.

Sebastien Bollue
CEO of Redsense Medical

This information is information that Redsense Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Market Act. The information was submitted for publication, through the agency of the contact person specified below, on May 20, 2026, at 08:30 CET.